Abstract
Mass vaccination was the most effective prophylaxis for protecting the population during the influenza H1N1 pandemic. We have evaluated the tolerability, immunogenicity and kinetics of the antibody response to a monovalent oil-in-water (AS03) adjuvanted human pandemic split influenza A/California/7/2009 H1N1 (3.75 μg haemagglutinin) vaccine in health care workers. Vaccination elicited a rapid and early protective level of haemagglutination inhibition antibody from 6 to 7 days post vaccination, and by 14 to 21 days post vaccination, up to 98% of vaccinees had protective antibody titres which persisted for at least 3 months in 84-92% of subjects. A rapid induction of protective antibody is important in reducing community spread of pandemic influenza and in helping maintain the integrity of the health care system during the pandemic.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antibodies, Viral / blood
-
Drug Combinations
-
Female
-
Health Personnel*
-
Hemagglutination Inhibition Tests
-
Humans
-
Influenza A Virus, H1N1 Subtype / immunology*
-
Influenza Vaccines / administration & dosage
-
Influenza Vaccines / adverse effects
-
Influenza Vaccines / immunology*
-
Influenza, Human / immunology
-
Influenza, Human / prevention & control*
-
Influenza, Human / virology
-
Male
-
Middle Aged
-
Polysorbates / administration & dosage
-
Polysorbates / adverse effects
-
Squalene / administration & dosage
-
Squalene / adverse effects
-
Time Factors
-
Vaccines, Subunit / administration & dosage
-
Vaccines, Subunit / adverse effects
-
Vaccines, Subunit / immunology
-
alpha-Tocopherol / administration & dosage
-
alpha-Tocopherol / adverse effects
Substances
-
Antibodies, Viral
-
Drug Combinations
-
Influenza Vaccines
-
Polysorbates
-
Vaccines, Subunit
-
Squalene
-
AS03 adjuvant
-
alpha-Tocopherol